Table 6.
The effect of biological interventions in the tracheal allograft model
| Dose | Treatment | Harvest | Luminal | Epithelial | Changes in | ||||
| Animal | Compound | (mg/kg per day) | time (days) | time (days) | occlusion (%) | loss (%) | cytokines/GFs | n | Reference |
| Rat | Control | - | - | 7 | 0 | <25 | 5 | [46] | |
| 21 | 50–75 | >75 | 5 | ||||||
| rIL-10 | 10 μg/ml | 0–14 | 7 | 0–<25 | 0–<25 | 5 | |||
| at 0.5 μg/h i.p. | 21 | 50–75 | >75 | 5 | |||||
| 5–14 | 7 | 0 | 0–<25 | 5 | |||||
| 21 | <25 | 50–75 | 5 | ||||||
| Rat | Control | - | - | 7 | 0–<25 | 0–<25 | 5 | [46] | |
| 21 | 50–75 | >75 | 5 | ||||||
| Adv-IL-10 | i.m. | 5 | 7 | 0 | 0–25 | 6 | |||
| 21 | <25 | 50–75 | 6 | ||||||
| Control | i.m. | 5 | 7 | 0 | 0–<25 | 6 | |||
| vector | 21 | 50–75 | >75 | 6 | |||||
| Rat | CsA | 25 i.m | 2–3 | [31] | |||||
| + 5 i.m. | 4–27 | 56 | Partial | 10 | |||||
| CsA | 25 i.m. | 2–3 | |||||||
| + | + 5 i.m. | 4–27 | |||||||
| IL–2 | + 90,000 IU i.p. | 15–19 and 22–26 | 56 | 100 | 13 | ||||
| Rat | Control | - | 28 | >75 | >75 | 5 | [37] | ||
| 42 | >75 | >75 | 5 | ||||||
| 56 | n.a. | n.a. | 5 | ||||||
| 70 | n.a. | n.a. | 5 | ||||||
| CsA | 25 i.m | 2–3 | 28 | 0 | 0–<25 | 5 | |||
| + 5 i.m. | 4–27 | 42 | 0–<25 | <25 | 5 | ||||
| 56 | 50–75 | 50–75 | 5 | ||||||
| 70 | >75 | >75 | 5 | ||||||
| CsA | 25 i.m. | 2–3 | 28 | 0–<25 | <25 | 5 | |||
| + | +5 i.m. | 4–27 | 42 | 25–50 | 50–75 | 5 | |||
| IL-2 | +300,000 IU i.p. | 15–19 and 22–26 | 56 | 25–50 | 50–75 | 5 | |||
| 70 | >75 | 50–75 | 5 | ||||||
| Rat | CsA | 1 s.c. | 0–3 | 3 | 15 | 61 | 10 | [60] | |
| 0–10 | 10 | 18 | 27 | 10 | |||||
| 0–30 | 30 | 86 | 0 | 10 | |||||
| CsA | 1 s.c. | 0–30 | 3 | 7 | 18 | TNF-α, IL-2, | 10 | ||
| + | + | + | PDGF-AA ↓ | 10 | |||||
| human sCR-1 | 20 i.p. | –1 to 7 | 10 | 8 | 26 | 10 | |||
| 30 | 52 | 0 | 10 | ||||||
| Rat | Control | - | - | 7 | 30 | 19 | 5 | [49] | |
| - | 21 | 90 | 100 | 5 | |||||
| Control Ab | o.m.p. infusion | 0–7 | 7 | 40 | 23 | 5 | |||
| 0–14 | 21 | 100 | 100 | 5 | |||||
| anti-RANTES Ab | o.m.p. infusion | 0–7 | 7 | 30 | 4 | 5 | |||
| 12 μ g/day | 0–14 | 21 | 35 | 84 | 5 | ||||
| Mouse | Control IgG | 200 μg/mouse i.p. | 0, 2, 4, 6 | 35 | 98 | 7 | [44] | ||
| CTLA4 IgG | 200 μg/mouse i.p. | 0, 2, 4, 6 | 35 | 27 | 7 | ||||
| Control IgG | 200 μg/mouse i.p. | 6, 8, 10, 12 | 35 | 91 | 4 | ||||
| CTLA4 IgG | 200 μg/mouse i.p. | 6, 8, 10, 12 | 35 | 42 | 4 |
Ab, antibody; Adv, adenovirus; CsA, cyclosporin A; GFs, growth factors; IL, interleukin; i.m., intramuscularly; i.p., intraperitoneally; n.a., not assessed; o.m.p., osmotic mini pump; PDGF, platelet-derived growth factor; rIL-10, recombinant IL-10; s.c., subcutaneously; sCR; soluble complement receptor; TNF, tumour necrosis factor.